These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35852878)

  • 21. An update on the pharmacogenomics of metformin: progress, problems and potential.
    Todd JN; Florez JC
    Pharmacogenomics; 2014 Mar; 15(4):529-39. PubMed ID: 24624919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes.
    Chikermane SG; Sharma M; Abughosh SM; Aparasu RR; Trivedi MV; Johnson ML
    Breast Cancer Res Treat; 2022 Oct; 195(3):421-430. PubMed ID: 35969285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes.
    Tseng CH
    Breast Cancer Res Treat; 2014 Jun; 145(3):785-90. PubMed ID: 24816805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term metformin use is associated with decreased risk of breast cancer.
    Bodmer M; Meier C; Krähenbühl S; Jick SS; Meier CR
    Diabetes Care; 2010 Jun; 33(6):1304-8. PubMed ID: 20299480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes.
    Rathmann W; Strassburger K; Bongaerts B; Kuss O; Müssig K; Burkart V; Szendroedi J; Kotzka J; Knebel B; Al-Hasani H; Roden M;
    Diabetologia; 2019 Feb; 62(2):286-291. PubMed ID: 30413829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes.
    Urpilainen E; Kangaskokko J; Puistola U; Karihtala P
    Tumour Biol; 2019 Jan; 41(1):1010428318815413. PubMed ID: 30803422
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.
    Oppong BA; Pharmer LA; Oskar S; Eaton A; Stempel M; Patil S; King TA
    Cancer Med; 2014 Aug; 3(4):1025-34. PubMed ID: 24944108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.
    Kim HJ; Kwon H; Lee JW; Kim HJ; Lee SB; Park HS; Sohn G; Lee Y; Koh BS; Yu JH; Son BH; Ahn SH
    Breast Cancer Res; 2015 May; 17(1):64. PubMed ID: 25935404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metformin and type-2 diabetes mellitus].
    Mata Cases M
    Aten Primaria; 2008 Mar; 40(3):147-53. PubMed ID: 18373928
    [No Abstract]   [Full Text] [Related]  

  • 30. PYK2 promotes HER2-positive breast cancer invasion.
    Al-Juboori SI; Vadakekolathu J; Idri S; Wagner S; Zafeiris D; Pearson JR; Almshayakhchi R; Caraglia M; Desiderio V; Miles AK; Boocock DJ; Ball GR; Regad T
    J Exp Clin Cancer Res; 2019 May; 38(1):210. PubMed ID: 31118051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells.
    Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
    Cell Cycle; 2009 Jan; 8(1):88-96. PubMed ID: 19106626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.
    Bayraktar S; Hernadez-Aya LF; Lei X; Meric-Bernstam F; Litton JK; Hsu L; Hortobagyi GN; Gonzalez-Angulo AM
    Cancer; 2012 Mar; 118(5):1202-11. PubMed ID: 21800293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metformin: fifty-two not out.
    Campbell IW
    J Indian Med Assoc; 2009 Nov; 107(11):779-84. PubMed ID: 20469782
    [No Abstract]   [Full Text] [Related]  

  • 34. Metformin as an addition to conventional chemotherapy in breast cancer.
    Grenader T; Goldberg A; Shavit L
    J Clin Oncol; 2009 Dec; 27(35):e259; author reply e260. PubMed ID: 19884518
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
    Nasykhova YA; Tonyan ZN; Mikhailova AA; Danilova MM; Glotov AS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it time to test metformin in breast cancer prevention trials? A reply to the authors.
    Barba M; Muti P
    Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2565; author reply 2565. PubMed ID: 19745224
    [No Abstract]   [Full Text] [Related]  

  • 37. Does use of metformin protect against cancer in Type 2 diabetes mellitus?
    Bo S; Benso A; Durazzo M; Ghigo E
    J Endocrinol Invest; 2012 Feb; 35(2):231-5. PubMed ID: 22490993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes.
    Vissers PA; Cardwell CR; van de Poll-Franse LV; Young IS; Pouwer F; Murray LJ
    Breast Cancer Res Treat; 2015 Apr; 150(2):427-37. PubMed ID: 25762476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Breast cancer subtypes and their endocrine-metabolic basis; practical aspects].
    Bershteĭn LM; Semiglazov VF
    Vopr Onkol; 2011; 57(5):559-66. PubMed ID: 22238924
    [No Abstract]   [Full Text] [Related]  

  • 40. Metformin for cancer prevention.
    Yang Y
    Front Med; 2011 Jun; 5(2):115-7. PubMed ID: 21695613
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.